These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22359870)

  • 1. [Experience with empirical treatment of severe acute respiratory syndrome due to coronavirus, genotype IV].
    Shchukina VN; Loginova SIa; Borisevich SV; Bondarev VP
    Antibiot Khimioter; 2011; 56(7-8):42-6. PubMed ID: 22359870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiretroviral drugs in severe acute respiratory syndrome].
    Yazdanpanah Y; Guéry B
    Presse Med; 2006 Jan; 35(1 Pt 2):105-7. PubMed ID: 16462674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
    Xie X; Jiang Y; Zeng Y; Liu H
    Antivir Ther; 2020; 25(4):233-239. PubMed ID: 32496210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers.
    Park SY; Lee JS; Son JS; Ko JH; Peck KR; Jung Y; Woo HJ; Joo YS; Eom JS; Shi H
    J Hosp Infect; 2019 Jan; 101(1):42-46. PubMed ID: 30240813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Present state of in vitro and in vivo studies on efficacy of medical nonspecific protective agents with respect to genotype IV coronavirus causing severe acute respiratory syndrome].
    Shchukina VN; Loginova SIa; Borisevich SV; Bondarev VP
    Antibiot Khimioter; 2011; 56(9-10):41-6. PubMed ID: 22586904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
    Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
    J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacologic treatment of SARS: current knowledge and recommendations.
    Tai DY
    Ann Acad Med Singap; 2007 Jun; 36(6):438-43. PubMed ID: 17597972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
    Chu CM; Cheng VC; Hung IF; Wong MM; Chan KH; Chan KS; Kao RY; Poon LL; Wong CL; Guan Y; Peiris JS; Yuen KY;
    Thorax; 2004 Mar; 59(3):252-6. PubMed ID: 14985565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caution With the Use of Lopinavir/Ritonavir in Severely Ill Patients for the Treatment of SARS-CoV-2: A Report of Severe Jaundice.
    Levy C; Lassailly G; Parmentier E; Duburcq T; Mathurin P; Poissy J
    Am J Gastroenterol; 2020 Oct; 115(10):1716-1718. PubMed ID: 32858566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.
    Smolders EJ; Te Brake LH; Burger DM
    Antivir Ther; 2020; 25(7):345-347. PubMed ID: 32589165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
    Kim UJ; Won EJ; Kee SJ; Jung SI; Jang HC
    Antivir Ther; 2016; 21(5):455-9. PubMed ID: 26492219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ritonavir- and lopinavir-induced eryptosis in a SARS-CoV-2-infected patient.
    Stalder G; Alberio L
    Blood; 2020 Aug; 136(7):915. PubMed ID: 32790855
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19.
    Yip TC; Lui GC; Wong VW; Chow VC; Ho TH; Li TC; Tse YK; Hui DS; Chan HL; Wong GL
    Gut; 2021 Apr; 70(4):733-742. PubMed ID: 32641471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir-ritonavir for COVID-19: A living systematic review.
    Verdugo-Paiva F; Izcovich A; Ragusa M; Rada G
    Medwave; 2020 Jul; 20(6):e7967. PubMed ID: 32678815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
    Vargas M; Servillo G; Einav S
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad-spectrum coronavirus antiviral drug discovery.
    Totura AL; Bavari S
    Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe acute respiratory syndrome: scientific and anecdotal evidence for drug treatment.
    Tsang K; Seto WH
    Curr Opin Investig Drugs; 2004 Feb; 5(2):179-85. PubMed ID: 15043392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.